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Personalized medicine is the natural evolution of medicine. More specific descrip-
tions of diseases and more precise characterization of patients are said to make it
possible to administer better treatment.
In this process towards more effective personalized medicine, biobanking could
play a crucial role. It could allow for storing a large number of high quality biosam-
ples linked to personal and medical data of the sample donor. The stored material
can be retrieved and used in research to detect actionable defining molecular char-
acteristics to classify patients in subgroups for certain diseases. Once proven in a
clinical setting, these molecular characteristics can be used to enable more effective
targeted prevention, diagnosis, and therapy.
The triangle model which is proposed in this thesis shall provide a guideline for
biobanking and research to better support personalized medicine. It consists of three
components – public, biobank, and research component – each with its respective
subcomponents.
Parts of the triangle model have been discussed in recent literature but some key
issues have not been addressed yet. These missing points are extracted in this work
and include: 1) the availability of a complete governance plan, 2) proper standards
for documentation and tracking of samples for quality control, 3) the use of electronic
forms, and 4) proper standards for reporting in scientific journals.
A guideline as provided by the triangle model would be useful for biobanking
to become a model for success for the support of personalized medicine. However,
due to the relevance of the topic, new findings and developments are made contin-
uously. Therefore, only time will tell if biobanking and research do indeed support
personalized medicine.
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11. INTRODUCTION
The vision of developing personalized medicine, a medicine where therapy and med-
ication is based on an individual’s unique characteristics in reacting to a disease, is
fueled by the increasing knowledge about the molecular basis of disease and health
status [1]. This molecular information can be used to highlight differences among
patients with the same disease and can be used to predict a patient’s response to
therapy. Administering drugs and therapy only in cases where patients will actually
benefit from them will save money in health care and save the other patients the
stress of unnecessary treatment [2].
Personalized medicine and the research to improve personalized medicine are
dependent on availability of high quality and well annotated human biosamples [1].
These samples can theoretically be provided by biobanks. Many thereof have been
established in recent years [3]. The principle of biobanking includes the collection,
processing, and storage of human biosamples and their related personal and medical
information [1]. To realize the promise of personalized medicine, biobanking has to
be done following standards to safeguard sample quality.
To my knowledge, there exists no structure or model which covers all aspects of
biobanking and research that are needed to support personalized medicine. However,
due to the demand for interoperability of biobanks, and the development of biobank
networks to share data and collaborate in research, the need for a common guideline
structure arises.
The aim of this thesis is to develop a model which shows the necessary steps
needed in biobanking and research to support the development of efficient person-
alized medicine. The individual components of the model are identified and parts
that have not been addressed so far or need improvement for the model to be usable
as a guideline in practice are uncovered.
This thesis is structured as follows. Chapter 2 provides the necessary background
information on personalized medicine, biobanking, and how both parts are con-
nected. The main focus is on the triangle model, which is introduced in Chapter 3,
listing its components and explaining each of them. Following this is the discussion
of parts of the model which are missing from prior reports in the literature and of
the situation in Finland in Chapter 4. Chapter 5 summarizes the work shortly and
presents future prospects of biobanking and the triangle model.
22. BACKGROUND
To fully understand the model presented in Chapter 3, it is important to have
some background knowledge. Therefore, I provide basic information on personalized
medicine, biobanks, and biobanking in this section.
However, this section does not only include definitions of the most important
terms. I also present information on the relevance of personalized medicine, biobank-
ing, and biobanks in the literature. I describe important subcomponents of personal-
ized medicine, the idealized biobanking process, and types and networks of biobanks
before connecting biobanking with personalized medicine.
2.1 Personalized medicine
There are multiple definitions of the term “personalized medicine” [4–10] but most
agree that through it, the right treatment is administered to the right person at the
right time [8]. This is a very general motto for personalized medicine and in fact it
also describes generally well-practiced medicine [6]. A more detailed description on
the definition of personalized medicine is given in the report of the US President’s
Council of Advisors on Science and Technology (PCAST) in September 2008, where
personalized medicine is stated to refer to the tailoring of medical treatment specific
to the individual characteristics of each patient [2]. It is further described as the
ability to classify individuals into subpopulations, which have different susceptibil-
ity to a certain disease or respond differently to a specific treatment rather than
creating unique drugs or medical devices for an individual patient. Through this
classification, those that will not benefit from the treatment will be spared from
expenses and side effects while the preventive or therapeutic interventions can be
concentrated on those that will benefit.
According to the PCAST report, personalized medicine is the natural evolution
of medicine. Through more specific descriptions of diseases as well as precise char-
acterization of the patients it will be possible to administer better treatments [6].
For precise characterization and classification in subgroups of the population, per-
sonalized medicine uses information about the patients’ genomes as well as their
environment and family history [10].
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2.1.1 Personalized medicine in the literature
Having the patients’ genomes as one of the parts needed to characterize them better,
it is not surprising that the enthusiasm about personalized medicine followed after
decades of research and the clinical translation in human genetics [10]. However,
medicine has always been personalized in some way. Doctors have long taken their
patients’ environment, medical history, and family medical history into account when
making treatment decisions [8].
The first paper mentioning the term “personalized medicine” was published in
1971 [11]. Another one followed in 1990 [12], however there were no further publi-
cations on that term until 1999 [13]. As it can be seen in Figure 2.1, from 1999 on,
more and more papers regarding personalized medicine were published.
Figure 2.1: Academic publications per year on the term “personalized medicine” in the
PubMed database. (Data of 08.03.2014)
The Human Genome Project was completed in 2003 [14] and provides information
on the human genomic sequence and on the sequence variations [15]. With this
information, the interest in personalized medicine increased and with it the research
in genomic medicine as well as in pharmacogenetics. However, the general interest
in this topic was not only sparked due to the promise of improved patient care and
disease prevention but also due to its potential to have a positive impact on health
care cost and medical product development [2].
2.1.2 Personalized genomics
While it is not the only component of personalized medicine, personalized genomics
plays a vital role in its development because genetic profiling is an important method
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used to classify individuals into subgroups [10]. Natural variations found in the
human genome can influence each individual’s risk for a certain disease [4]. The
most important impact of these variations is how they affect the metabolism of an
individual or tumor development. According to the behavior of the metabolism of an
individual, the subtype of the disease can be determined. This knowledge can help
physicians to select individual treatments and dosing of drugs leading to practical
personalized medicine [4, 8].
To classify the subtype of a disease it is important to analyze certain biomark-
ers [4]. A biomarker is defined as any substance or biological structure in the human
body that can be measured and may influence, predict, or explain the occurrence or
outcome of a disease [16]. Because of their characteristics, biomarkers are gaining
importance for personalized medicine in applications such as diagnosis, prognosis,
and selection of target therapies. Mature genomic technologies and decreasing costs
of genomic sequencing are helping in generating a flood of biomarkers and compa-
nies offering biomarker services [5]. A good way to improve medicine and progress
towards personalized medicine is to improve the technology and techniques to detect
biomarkers in a way that a physician can check a patient’s genome in an easy, fast,
and cheap way prior to prescribing a particular drug or treatment [4].
2.1.3 Personalized cancer medicine
Personalized medicine is becoming a viable option in oncology through enabling
more personalized cancer treatment. This application of personalized medicine in
oncology is often referred to as personalized cancer medicine. [5]
Oncologists have long understood that individual patients with cancer have dif-
ferent clinical presentation, prognosis, tumor response, and tolerance to treatment.
However, only with the recent progress in research and the understanding of the vari-
ation in the human genome, scientists and clinicians have started to understand the
heterogeneity of cancer. This knowledge has moved the field of cancer therapeutics
in new directions. These directions include developing therapies that aim to break
molecular pathways in tumors responsible for cell growth and survival, creating a
molecular profile of tumors to have a better chance to assess prognosis and likelihood
of benefit from treatment, developing single- or multigene expression signatures of
response or resistance to certain drug treatments, and developing immunological
approaches specific to an individual tumor such as vaccine therapies. [17]
The individual gene expression profile can be used together with a statistically
defined algorithm to determine a recurrence score which will show if the patient is
likely to benefit from additional accompanying therapy. Patients with low recurrence
scores, giving them good prognosis, can be spared unnecessary therapy and the
health care system can save the cost for the treatment. [6]
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As cancer biology research continues and genome profiling activities advance,
more will be known about cancer and tumors and more drug targets will be revealed.
Personalized cancer care is becoming reality in clinical assessment and management
of patients. These two factors fuel the expectation to improve treatment efficacy
through better defined targets, reduce toxicity through individual drug dosage, and
minimize cost through avoiding redundant therapy. [17]
2.1.4 Drug administration
Another big opportunity for the growth of personalized medicine is the development
of drugs. Long did researchers believe that there is no progress in personalized drug
development because large pharmaceutical companies were not interested. They had
their blockbuster model where one drug has to fit for everyone and research for indi-
vidual metabolisms was not part of the plan. Only with the technological advances
that simplified and cheapened genomic research, and increased the availability of
biomarkers, pharmaceutical companies became interested. [5]
Personalized medicine is especially important when looking at the standard drug
treatments. There are big variations depending on the different diseases treated,
however, between 30% and 70% of the patients will not respond to a given drug
treatment [6]. While many different factors could in fact influence the drug re-
sponse, it seems highly probable that individual drug metabolism rates and natural
variations in the disease characteristics are also contributing. Therefore, the develop-
ment of personalized drug treatment will make drug use safer because an accidental
overdose due to metabolism differences is prevented [9].
2.2 Biobanking
In this thesis, a biobank is defined as a collection of human biological samples and
their associated data, stored in an organized form for the purpose of research [18].
Included in the data stored with the samples are clinical information taken from
the person’s health record as well as personal, lifestyle, behavioral, environmental,
socioeconomic, and demographic information [19]. Biobanking includes the process
of collecting, processing, handling, storing, and eventually distributing and sharing
of samples and their associated data with researchers accessing the biobank [20,21].
The sample, often referred to as biospecimen, can be of a wide variety such as
cells, tissue, blood, or DNA for example. The type of sample that is collected usually
depends on the purpose of the collection. [19]
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2.2.1 History of biobanking
The first time the term “biobank” appeared in the literature was 1996 [22], not even
20 years ago [23]. As seen in Figure 2.2, only about 10 years later the number of
papers containing the terms biobank or biobanking increased significantly.
Figure 2.2: Academic publications per year on the terms biobank or biobanking in the
PubMed database. (Data of 08.03.2014)
The process of storing human biological samples and associated clinical and re-
search data, however, is not a recent development [24]. Collections of samples for
research have been curated by researchers for more than a century. The first sys-
tematic collections of human cells and tissues began in the 19th century [25]. Those
early biobanks, as they were developed in Europe for example during the 1930s had
different purposes and operational mechanisms [26]. Only in the late 20th century
were biobanks initiated that allow for coupling of the biological and genetic data
with the general patient data [25]. The term biobank has come into use as the scale
of such collections has vastly increased and the locus of organization has expanded
to include individual research groups, entire institutions, and in many cases whole
countries [27].
Two developments in life science encouraged the creation of “industrial size”
biobanks currently in place and development. First, there have been methodolog-
ical breakthroughs in molecular biology which offered new possibilities for medi-
cal research [26]. Especially in the understanding of genomic information and ge-
netic mechanisms in diseases, it became important to be able to store large collec-
tions of samples together with the associated health data and clinical activities over
time [28]. Second, developments in information and robotic technology, as well as
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bioinformatics, have provided methods to collect and analyze large data and sample
numbers [26].
2.2.2 Process of biobanking
The storage of samples and their associated information is only one part of the
biobanking process. A simplified version of the most important steps of an idealized
biobanking process and the interactions with the biobank can be seen in Figure 2.3.
CONSENT
BIOLOGICAL 
SAMPLE
ASSOCIATED 
INFORMATION
PROCESSING STORAGE
RESEARCH / 
STUDY
RESULTS
SCIENTIFIC 
PUBLICATION
BIOBANK
(a)
(c)
(d) (e)
(b)
Figure 2.3: Systematic path of the biological sample and its relevant information. The
biobanking process starts with the collection of the sample, associated information, and
the consent (a). Then the samples and information are processed and stored (b) until
needed. Researchers query the database of the biobank (c) and ask for samples that
will be delivered to their laboratory (d). After concluding their research, the results and
possible links to scientific journals are stored in the database (e).
Before samples can be stored, they have to be collected from the prospective
sample donor, which can be a patient at the hospital or a volunteer. In some but not
all instances, biobank collections are driven by researchers’ needs for specific studies,
and in many instances collections occur to support population-based research which
often cannot be specified completely in advance. [29]
At the point of sample collection, an appropriate form of consent is required,
depending on the type of study which is conducted [30]. Informed consent is seen
as protecting the autonomy of the participants and allowing them to exercise their
fundamental right to decide whether and how their donated samples and the asso-
ciated data can be used in research. According to the Declaration of Helsinki, only
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voluntary participants are allowed to enroll in medical research and they must be
sufficiently informed about the research [29]. To assure this, the informed consent
has to contain information about the aims and methods, any possible conflicts of
interest, the funding sources, institutional affiliations of the researcher, the expected
benefits and the potential risks or discomforts of the study, post-study provisions,
and any other aspects of the study that might seem relevant. The participants have
to be additionally informed about their right to refuse to take part or withdraw their
consent at any time without giving a reason. The whole content of the informed
consent has to be understood by the participants and signed to become valid.
Once the consent is given and the samples and information are collected, they are
labeled with a unique identifier in the database and then transferred to the biobank
which is depicted by (a) in Figure 2.3 [31]. This early labeling of samples should
assure that there is no mix-up or accidental mislabeling later on. The labeling
also makes it possible to disconnect personal information that is not relevant for
research but necessary for possible later identification of the donor from the sample
and health related information. Often, the collected samples are used to answer to
research questions arising after the initial study, or certain tests could be rerun in
the future with new technology or techniques [32]. To reduce the number of freeze-
thaw cycles a sample is exposed to, it is divided into separate aliquots that are
then labeled and frozen individually. Furthermore, depending on the purpose of the
study, the aliquots are not necessarily just split up parts of the same material but
they can also hold different material types, such as DNA or RNA, from the initial
sample.
After processing, the samples are stored in a way appropriate for the sample ma-
terial and the intended research purpose which is marked in Figure 2.3 by arrow (b).
In most cases, the aliquots are stored in -80 ◦C freezers since only few biomolecules
other than DNA preserve well at only -20 ◦C. Many of those -80 ◦C freezers in bigger
biobanks are automated, so that the stored samples are not disturbed by temper-
ature changes whenever the door is opened to retrieve a sample. An automated
freezer works like a vending machine. The sample is selected from the outside, a
mechanical arm then picks it up from the shelf and releases it in a hatch. [33]
No matter in what way the samples are stored, what processing they went
through, or into how many aliquots a sample was divided, everything has to be
documented and stored in the database of the biobank linked to the unique iden-
tifier of the collected sample. This information is important for sample tracking,
quality assurance, and specimen availability for future research [32]. Researchers
may query the database of the biobank through an interface shown in (c) in Fig-
ure 2.3 [34]. They can get additional information about a sample from their study,
see if more aliquots of a certain kind are available, or request a sample for research.
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The ordered sample is then retrieved from the storage, packed and sent to the re-
search laboratory, marked by (d) in Figure 2.3, and again the documentation linked
to the sample has to be updated.
The results are fed back to the biobank after the research was conducted. This is
shown in Figure 2.3 by arrow (e). It is important since genetic and genomic research
might reveal information and results of clinical relevance for an individual [35].
Although it is not common practice today, efforts are underway for participants
in a study to be given an option to be informed about the general outcomes and
results of the study [29]. To simplify a possible recontacting of those donors and
help for future research, the results are linked to the original unique identifier in the
database [24]. If the results of the study are to be published, also these scientific
publications should be linked to the used samples. This will help to provide detailed
information on the biospecimen and its processing, to make the published results
comparable and the study repeatable [36].
2.2.3 Types of biobanks
Biobanks are often developed according to the research question at hand. This
results in a variety of several different types of biobanks such as disease-oriented
biobanks, population-based biobanks, tissue biobanks, biobanks for clinical tri-
als, case-control biobanks, biomolecular resource centers that store antibodies, cell
biobanks for cord blood or stem cells, and more [37]. However, many of these
biobanks are similar in their structure and therefore two major formats of biobanks
can be distinguished; population-based and disease-oriented biobanks, and all the
other biobanks form subgroups to these categories [38].
Population-based biobanks
Population-based biobanks store biological samples and their associated data from
consenting volunteers from a defined population. The collections are usually used for
studies about common diseases in a population or the given risk factors for a disease.
The main idea behind population-based biobanks is to screen the population and
later on allow researchers to study the onset of a disease from the collected data over
time. To achieve this goal, the typical sample types that are collected are blood and
isolated DNA, together with primary information on data about the family history,
lifestyle, demography, and environmental exposures. [38, 39]
It is possible to find biomarkers that are responsible for a disease already present
in the healthy individual. This makes population-based biobanks an important tool
for preventive medical programs. Furthermore, the observation of occurrence and
progression of a certain disease in a specific population subgroup makes it interesting
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for different researchers. However, establishing large population-based biobanks is
expensive and challenging. [38]
Another issue is the continuous personal involvement of the participants. There
need to be several follow-up collections as well as accurately updated health informa-
tion. Without this information researchers are not able to make a valid prediction
on possible biomarkers, drug response or efficacy. [38,39]
Disease-oriented biobanks
By comparison, disease-oriented biobanks contain collections of tissue, cells, blood,
or other body fluids of a variety of diseases and associated healthy controls. Together
with the sample, biobanks of this type primarily store information from the health
records of the participants. [18,38,39]
Disease-oriented biobanks can be very specifically focused on only one disease
such as AIDS, diabetes, or any type of cancer or they can be focused on only one
sample type such as tissue banks or cell banks. Such biobanks are usually connected
directly to a hospital unit or research laboratory specializing in that field. [28]
The importance behind disease-oriented biobanks is that they offer a chance of
comparing different stages of a disease from one participant. Furthermore, they
allow researchers to compare a participant with a disease with healthy controls or
to compare the forms of a disease for different patients at a certain stage with each
other. By doing this on a molecular level researchers can make novel findings on
the disease characteristics as well as identifying biomarkers and possible targets for
drugs. [38, 39]
2.2.4 Networks of biobanks
Biobanks nowadays exist on every continent, including Antarctica [40]. Having
samples in so many individual biobanks leads to a fractioning of the overall donated
materials available [38]. This can be problematic, since large numbers of samples are
needed for statistical significance of findings. Another issue is that if one biobank,
even if it were a big institution itself, would have to collect all these samples, it would
take years if not even decades to complete. Furthermore, for some studies several
follow up collections of samples have to be made so that the actual research cannot
start earlier than 10 to 15 years after starting the collection. Such a long collection
interval can have negative influence on the results, since new scientific insights and
changing techniques as well as the aging of the samples play an important part in
the outcome of the study [20,41].
One solution to the problem is data sharing and working together of several
biobanks, forming biobank networks. A survey published in 2010 [42] shows that
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biobanking already is a highly networked activity both in Europe and worldwide.
Especially in Europe there is a strong collaboration between biobanks, shown by
the result of almost 90% of biobanks interacting with at least one other group.
Already more than 50% of European biobanks share international data and samples
regularly, and one third of them have formed permanent partnerships with other
local, national, or international biobanks. [43]
This cooperation of biobanks leads to an increase in statistical power and sample
size [28]. Especially smaller biobanks can increase their power by joining together
in networks to conduct research studies. Another advantage of biobank networks
is that the probability of sample usage increases. There are many samples and
associated data collected that are stored but never used [44]. This is often due to
only few people knowing about those samples. By working together in a network
and providing a searchable catalog of all the samples in the biobanks of the network,
researchers will easier find fitting samples for their research.
However, biobank networking also brings up some challenges that need to be
overcome. In these new global networks, biobanks are the nodes on the information
flow between institutions and researchers that make data and sample storage, orga-
nization, and reconfiguration for different research projects possible [45]. To achieve
this seamless interaction between biobanks, it is important that some harmonization
for their procedures for collecting and storing data and samples exists [20]. Only by
harmonizing standards and following general ethical and legal rules, samples from
different biobanks in the network render comparable and are usable in the same
study. This interoperability leads to a more efficient structure to pool, analyze, and
share biological samples. It will allow the scientific community to gain access to
samples of comparable quality and more complex amounts of information.
One of the largest biobanking networks in Europe is the Biobanking and Biomolec-
ular Resources Research Infrastructure (BBMRI), which is funded by the European
Commission. Its goal is to provide comprehensive collections of biological samples
from Europeans, linked with continuously updated data on health, lifestyle, and
environmental influences of the sample donors. Through the creation of a single
centralized infrastructure, it will increase the scientific excellence and research effi-
ciency in Europe, ensure competitiveness of European research, and attract invest-
ments from outside of Europe. The BBMRI will consist of biomolecular resources
and biobanks of different formats as well as harmonized standards to simplify data
and sample exchange. Since the end of the preparation phase in early 2011, BBMRI
has evolved into a consortium of 54 members and over 225 associated organizations
from over 30 countries. [46]
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2.3 Biobanking in personalized medicine
The evolution towards personalized medicine largely depends on the availability of
research data. Its promise of customized treatment for each individual is seen to
enhance patient care and reduce treatment costs by focusing on personal genetic
data [47]. As described in Chapter 2.1, one of the important factors for success of
personalized medicine is biomarker research. The search for biomarkers bridges mul-
tiple disease areas, clinical specialties, and drug development. Yet, it is dependent
on large numbers of high quality samples [48].
Biobanks are the tools to be used to provide the required large collections of sam-
ples linked to sample related information as well as personal and medical information
on the sample donor [46,47]. Furthermore, biobanks also enable linking clinical out-
comes to stored specimen, allowing clinical personal a much broader assessment of
the genetic variations across a range of conditions [49]. Therefore, researchers be-
lieve that biobanks can play an important role in the development of personalized
medicine by providing reliable samples and information [28,39].
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3. TRIANGLE MODEL
As previously mentioned, biobanking could be essential for the development of suc-
cessful personalized medicine. Based on literature review I have created the triangle
model shown in Figure 3.1. It presents the components to be considered when
developing biobanking as support for personalized medicine. It displays a trian-
gle around biobanking, research, and personalized medicine together with its three
support components.
Personalized medicine
Biobanking
  
Research
Public component
Research component
Biobank component
Figure 3.1: Triangle model – depicting the three driving components that ensure biobank-
ing and research are leading to personalized medicine.
The presented three support components in the model are the public, biobank,
and research component. They form the driving force for biobanking and research
to lead to personalized medicine. In the following sections, the parts of these three
components are evaluated separately in context of supportive biobanking. For each
section, first the literature information if available and then my own view about
each section is presented.
3.1 Public component
The public component is a very important component of the triangle model because
a biobank could not exist without samples. These samples need to be voluntarily
donated by the public to lay the foundation of a biobank and start the process of
biobanking. However, the public does not only play a role in the beginning of the
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biobanking process, as its support is also important for further success of biobanks.
As it can be seen in Figure 3.2, the public component of the triangle model
consists of two parts, the sample provision and consent. It mainly concerns the
prospective participants in biobanking studies and other sample donors.
Personalized medicine
Biobanking
  
Research
Public component
Research component
Biobank component
● Sample provision
● Consent
Figure 3.2: Triangle model: detailed view of the public component with its parts.
3.1.1 Sample provision
Sample provision indicates the donation of biosamples together with the correspond-
ing personal and health related information. Here I discuss two issues that should
be taken into account when talking about sample provision: 1) public education
about biobanking, and 2) making donation as easy as possible for the participants.
The advantage of education can be seen on the number of volunteers and the time
the donation will take as visualized in Figure 3.3.
Education about biobanks
To conduct research that is in support of personalized medicine, large numbers of
samples with great diversity are required to be stored accessibly in biobanks [39].
Many different participants are needed and can most easily be recruited by edu-
cating the public about the necessity of biobank collections [47]. Education of the
public and promotion of biobanks is important for the initial success of biobanking,
according to a study by Georg Gaskell and Herbert Gottweis based on the 2010
Eurobarometer on biotechnology [50]. It shows that people are more likely to join
biobanking research if they are aware of its existence and importance. Few people
3. Triangle model 15
(A)
(B)
Co
ns
en
t
Co
ns
en
t
Figure 3.3: Sample provision: In case of good public education, more people will participate
and the consent provision will take little time (A). If there is no or little public education,
few people will participate and providing consent will take a long time (B).
allow for their samples to be kept in biobanks because there is little education on the
topic and the public fears that the stored information could be used against the donor
in the future [47]. In case of patient groups, however, it shows that they want to
support biobanking research. Some patients’ organizations even run and/or finance
their own biobanks [25]. Public trust and confidence in biobanking are the most
important points for the success of biobanking [39]. Not only information about
the purpose of the biobank and its operation but also about the resulting social
benefits should be provided. This information can be shared in seminars, work-
shops, surveys, interviews, genuine discussions among community members, health
center meetings, social network forums on the internet, as well as in other media
sources. Another option to educate the public is to arrange meetings with previous
donors to bring the discussion to a more personal level [39,47]. In finding a way how
to approach the public, it is also important to learn from their doubts and fears [50].
Following this, I assume that people who know about the long-term benefits of
biobanking will be more likely to participate in biobanking studies and donate sam-
ples and information. Furthermore, teaching about biobanking will prevent the
spreading of fear through wrong or misunderstood information.
One way to bring biobanking closer to the public is, as suggested, through in-
formation sessions which are conducted by professionals in this field and previous
donors who can describe their experiences and why they decided to take part in
a study. This would give potential participants a chance to ask questions and talk
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about their concerns with people that have personal experience. Such sessions can be
especially suitable for population-based biobanking studies because they can easily
be coupled with the process of recruiting participants. For disease-oriented biobank-
ing studies a good way would be to directly involve physicians. They can hand out
information to patients and explain the advantages of research involving biobanks
in their special case.
Overall, I believe that patients who have a certain disease donate samples more
probably because they hope that this kind of research can find a better cure and
therapy. They understand the benefits of biobanking research and the resulting
personalized medicine and are more easily convinced to take part. In case of the
general population it can be more difficult as they are not directly affected and for
them possible risks weigh more than imminent benefits.
Uncomplicated donation
To get as many voluntary participants as possible it is important to make sample
and information donation as easy as possible. In my opinion, there are two different
approaches for simple sample and information donation.
In one case, the prospective participant is a patient already admitted at a hospital.
This is often the situation for disease-oriented biobanks such as tissue banks that
collect cancer tissue from a removed tumor. Having the participant already at the
hospital has the advantage that the patient can stay at the same place for sample
donation. Hospital staff can collect the removed tissue or other samples as they
would do other hospital routines. The disadvantage is that the donation of samples
is only a byproduct to the actual treatment and the patient has enough own worries
in that situation. I think, even though most patients are willing to donate samples
for biobanking research, if approached at the wrong time or in the wrong way they
might feel exploited and disagree to sample donation.
The other case is that volunteers have to come to either the biobank directly
or a designated physician for the collection. The advantage of this kind of sample
collection is that it is precisely done as wanted because it is the main focus of the
collection process. Additionally, if the donation is done at the biobank itself the
sample does not have to be shipped but can be stored or processed right away. The
disadvantage is that healthy volunteers have to come to certain sample collection
points. This requires personal effort. In my opinion, this is the greatest disadvantage
of sample donations and is one of the reasons why people might choose not to
participate.
However, there is not just the biological sample that needs to be collected. Par-
ticipants also have to provide personal and medical information needed for research.
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Filling out questionnaires can take time and can be bothersome for the participant.
Likewise can no connections between research results and medical history be made
if not all details are asked for in the questionnaire. Especially patients with a long
medical history do not want to write everything down, something might be forgot-
ten, or an issue that does not seem important at that point could eventually be
the key to solving a research question. To reduce the error potential and save time
and trouble for the participants, I think that, whenever available, the person’s med-
ical record should be directly connected with the sample information stored in the
biobank’s database.
3.1.2 Consent
According to Paragraph 32 of the Declaration of Helsinki, informed consent must be
obtained for the collection, storage, and/or reuse of material and data for biobanking
research [29]. Informed consent documents grant participants’ wish to know what
their samples are used for and protect their rights [1]. However, they also limit
biobanking research because the participants have to be informed about the concept
of biobanking, the purpose of the respective research project, and how its results
may affect them in the future before collecting any sample or information [20].
Many biobanks have instead decided to use the form of “broad consent” which
allows for future research by not defining in which research project the sample will
be used to avoid the limitations of informed consent [28]. According to various
studies conducted in 2012, there are no clear preferences between broad and informed
consent in research participants [51]. Within the biobanking community there is
strong support for broad consent, and most population-based biobanks in Europe
are using a broad consent model [52]. However, there are further specifications to the
reuse of samples with a broad consent such that any previously undefined research
has to be appropriately supervised by an institutional review board (IRB) or a
research ethics committee (REC) [47]. This would be in line with the Declaration
of Helsinki that states in the second part of paragraph 32 that for situations where
acquisition of consent is impossible or impracticable, research may be conducted
after consideration and approval from a research ethics committee [29].
Furthermore, there is also the possibility to use “tiered consent” which gives par-
ticipants a number of options on the consent form to govern the future use of their
donated samples and information which participants can select according to their
preferences [28,51]. Another proposed model is “dynamic consent” which gives par-
ticipants the possibility to give consent over a long period of time [37]. In the
dynamic consent model participants give informed consent to one study when the
samples are collected and receive a web account where information on the use of
their sample is available. Through this platform researchers can ask for additional
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informed consent for future studies along the way and donors can agree if interested.
The mentioned types of consent are compared in Table 3.1.
Table 3.1: Comparison of the various consent types: informed consent, broad consent,
tiered consent and dynamic consent.
informed broad tiered dynamic
Information on research study X - - X
Information on area of sample use - X X -
Future use of samples - X X X
Allows sample sharing - X X X
Constant involvement of donor - - - X
Research type chosen by donor - - X -
Right to revoke consent X X X X
Another problem with consent is linked to the sharing of samples. The breadth of
donor consent is a critical determinant of the interoperability of biobanks [43]. There
is an imminent need for an international guideline to facilitate data exchange [53].
A bridged consent for the use of a sample in more than one research laboratory
cannot be achieved if informed consent is a requirement.
Giving consent to the use of information and sample in research is in my opinion a
crucial element of the biobanking process because it protects the legal rights of the
donors and allows the storage and use of their samples. However, there are several
important aspects that need to be discussed such as the understandability of the
consent and which are the detailed information it is supposed to hold.
It is necessary for the participants to read and understand the consent form before
signing it to attest their voluntary participation. To ensure the understanding of
the form, a consultant should be available for any questions. Another possibility is a
short documentary about the biobanking process and the research. This should also
explain what will happen to the donated biosamples and the corresponding personal
and health information. It can also address some fears of donors about their rights
and the protection of their privacy and information. To find out about the most
widespread fears, it can be useful to make surveys and directly ask people about
their reasons, if they choose not to participate.
Another point is the right of participants to know what they are participating in.
It is important that donors know what their samples are used for, even though this
also brings about the unique problem for biobanking research of informed versus
broad consent. The true potential of biobanks is that they can hold the collection
of many donors with different health backgrounds. As research progresses, these
samples are becoming useful for follow up studies or other research which has not
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been considered at the time of collection. For those cases it is not possible to
describe the precise study or research plan in the consent form. Therefore, it should
be possible to give some wider idea of what the usage of samples will be to not limit
the options of biobanking research. Even having a wide original scope and allowing
donors to then limit the scope if they do not agree, will still provide more possibilities
for research than getting consent for only one study. Another way to deal with the
reuse of samples would be to recontact participants. This is however often difficult
because people move away, die, or they just do not want to be contacted again. The
dynamic consent model could solve parts of this issue by providing a web interface
for participants through which they can be connected. However, I think this model
can only work if participants want to be involved with research because it requires
their further involvement.
In my opinion, broad consent – or at least wider consent than informed consent
for only one study – is the path of choice for biobanking research. Another option
is to let participants choose a dynamic consent approach and agree to give consent
continuously. For biobanking research to support personalized medicine, it is impor-
tant to reuse the sample and recontacting participants will be bothersome for both
parties, the researcher and the participants. Furthermore, I think it is important to
share data with other research institutes and access samples from other biobanks,
wherefore a wider form of consent is needed. However, there need not be a prob-
lem with the interoperability of biobanks if they have different consent conditions.
As long as the content of the consent is stored with the biobanked sample, it is
straightforward to only access samples that can be used for certain research.
3.2 Biobank component
The second component of the triangle model is the biobank component. It contains
the parts of the model that are directly applicable to the biobank itself and mostly
concern how the biobank is run and what precautions are taken to avoid its failure.
As it can be seen in Figure 3.4 the biobank component of the triangle model
consists of five parts: standards implementation, quality control, coordinated gov-
ernance and regulations, dynamic creation and destruction, and economic analysis.
3.2.1 Standards implementation
Due to the importance of human biospecimen for personalized medicine they have
to be collected and processed based on certain standards to guarantee quality and
annotation with the correct patient-related and sample-specific information [1]. To
ensure this, biobanks need to adopt and implement best practices which include
policies and standard operating procedures (SOPs) [36].
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Personalized medicine
Biobanking
 
Research
Public component
Research component
Biobank component
● Standards implementation
● Quality control
● Coordinated governance and 
regulations
● Dynamic creation and destruction
● Economic analysis
Figure 3.4: Triangle model: detailed view of the biobank component with its parts.
A number of different organizations have proposed best practice guidelines for
biospecimen repositories over the past 15 years [36,54]. A summary of the provided
information from the Australasian Biospecimen Network (ABN) [55], International
Agency for Research on Cancer (IARC) [56], International Society for Biological
and Environmental Repositories (ISBER) [57], National Cancer Institute (NCI) [58],
Organisation for Economic Co-operation and Development (OECD) [59], and RAND
Science and Technology (RAND) [60] is shown in Table 3.2. In addition to guidelines
about biospecimen handling such as collection, processing, and storage, also broader
issues such as ethical, legal, and social aspects, and regulatory requirements as well
as data and quality management are mentioned [54]. These best practice guidelines
shall ensure the level of quality for the samples in the biobank. Furthermore, the
use of best practice guidelines will lead to an economic benefit in the long run.
The guidelines proposed in [55–60] are mostly only suggestions or state some
minimum criteria that can be followed because some biospecimen management steps
are governed by national/federal, regional, and local regulations which have priority
over the proposed best practice guidelines [57]. The newest and most complete set
of guidelines is given by ISBER. Their 2012 version is the third edition after the first
in 2005 and the second in 2008. Hence, ISBER has invested 7 years of revision in
the current document, which explains the variety of information available. However,
ISBER is not specialized on human biospecimen repositories or biobanks but pro-
vides best practice guidelines for general repositories used for the collection, storage,
retrieval, and distribution of biological materials for research. There is a variety of
biobanks with specific differences so that each will have to set up their own guide-
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lines individually [41]. However, not many biobanks publish their own standards
which they apply based on the provided guidelines. The variety of procedures used
in different biobanks poses a significant problem if they want to collaborate with
each other [20].
Table 3.2: Recommendations for biosample repositories collecting human biospecimen.
Inspired by [61]. M = is mentioned / GL = guideline or protocol to follow is proposed /
* = sample type dependent.
RAND IARC OECD ABN NCI ISBER
Publication date 2003 2007 2007 2009 2011 2012
Funding /
Sustainability
M M GL - GL GL
Facility - - GL - M GL
Equipment - M GL - GL GL
Staff training M M GL - GL GL
Biosafety - GL GL - GL GL
Consent GL M M GL GL GL
Intellectual
property
GL M M - GL M
Privacy protection GL - M M GL GL
Sample Collection
and Processing
GL GL* M GL* GL GL*
Sample Storage GL GL* GL GL* GL GL
Transportation /
Shipping
GL GL* - GL GL GL
Traceability /
Labeling
M GL M M GL GL
Quality Control GL GL M GL* GL GL
Clinical Data
Management
- - - GL GL GL
Personal Data
Management
- - M - - GL
Sample-related
Data Management
M GL GL - M GL
Database M M M GL GL M
Access Right GL GL M GL GL GL
International
Exchange
- GL - M - M
Since existing biobanks already have their own practices specific to their biobank,
it would not make sense to demand complete uniformity among biobanks for col-
laboration [37]. Therefore, harmonization is used as a more flexible approach to
ensure the effective interchange of valid information and samples. While standard-
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ization would require the exact same protocols and SOPs to be used by all biobanks
which is only necessary in case the processes need to be identical, harmonization is
context-specific and relates to the compatibility of methodologies and approaches
to facilitate cooperation between biobanks [24]. The harmonization of best practice
policy guidelines and agreement on SOPs for laboratory procedures is important due
to the necessity of collaborations between biobanks to improve biobanking research
for personalized medicine [28, 36, 52]. However, there are not many organizations
and networks which are successfully sharing common harmonized protocols [20].
The BBMRI is an international biobanking network with the goal to better co-
ordinate biospecimen access and research activities across Europe [62]. They are
coordinating their plans with those already in place proposed by the Public Pop-
ulation Project in Genetics (P3G), the OECD, and the IARC. The P3G has done
a lot of work on collecting biobanking tools which are available in the toolkit on
their website [63]. The BBMRI Legal WIKI provides a collection of common min-
imum standards that need to be followed by any member no matter what other
laws, standards and guidelines they have in place [64]. Those standards focus on
ethical principles, regulation of use, and accessibility of the biobank and its sam-
ples. A schematic image of the different levels of proposed standards is displayed
in Figure 3.5. The BBMRI Legal WIKI also provides several templates for Euro-
pean biobanking research for the standard personal data processing security agree-
ment, material transfer policy and agreement, data access policy and agreement, and
biobank feedback policy [65]. Furthermore, documentation about past and present
EU biobanking projects is available as well as templates for national biobanking
research or national data processing notification requirements, and templates for
biobanking research with non EU countries. Many of these templates are not yet
filled and unfortunately there are no references on the use of any of the provided
templates.
Standards are important in biobanking to ensure that each process step is done in
a predefined way. However, it is not enough for standards to merely exist, they also
have to be applied for each processing step and linked to the processed sample.
They have to be used for the collection of samples, medical, and personal infor-
mation as well as for the consent. Different sets of standards need to be available,
depending on the sample type and the form of consent used. Furthermore, specific
standards should be used for every step along the way of processing that a sample
is going through. The implemented standards for these steps depend on the sample
type, the processing goal, and devices and expertise available. In addition to that,
the processing of the personal information needs to be standardized. Standards
should be used to decide how personal information is secured, stored, and protected
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Figure 3.5: The standard hierarchy biobanks are facing when they want to interact in a
network. A biobank in a certain nation needs to implement its own internal standards,
national laws and regulations, and minimum standards proposed by the network when
joining a network.
as well as who will have access to this information. Further standards that are im-
portant determine the access rights and conditions to the database of the biobank
and the minimum data set of information on the stored samples that researchers can
access. There seem to be already several proposed standards that can be followed
if a biobank chooses to do so. But still most biobanks seem to implement their own
standards or change the proposed guidelines to fit for the purpose of their biobank.
This does not pose a problem, as in most cases, harmonization is more important for
cooperation than the standardization of procedures. However, one problem is that
only few biobanks have their best practice standards accessible. Providing them to
the public would make their work more transparent and could increase the public’s
trust.
In my opinion, standard implementation becomes especially important when con-
sidering the cooperation with other biobanks. In that case it is important to know
the standards of the respective other biobank to see if the samples are comparable
or of sufficient quality for the intended research. More harmonization guidelines are
required to ensure the interoperability of biobanks. These guidelines should propose
a way to evaluate various dissimilar standards for different biobanks to know if their
samples are comparable.
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3.2.2 Quality control
High-quality human biospecimen are important for personalized medicine [1, 39].
The quality of the specimen is directly proportional to the richness of the associated
data profile and the confidence of researchers in the completeness and validity of the
information [1]. For biobanks the quality of their stored specimen is a key factor in
their success [20, 36]. However, studies from 2011 show that there are not enough
samples of sufficient quality available [33, 36,52].
To increase the number of high quality human biospecimen stored in biobanks,
quality control and quality management processes are adopted to enforce and test
quality standard usage [25, 43]. Proper documentation of any processing step that
could influence the sample quality is important since the interoperability between
biobanks requires not only high-quality but especially known quality specimen [51].
Four levels of quality applicable to biobanks have been suggested in 2005 [32]:
• training and certification of biobank staff and assignment of responsibilities,
• instrument maintenance,
• property control of processed materials, and
• long-term control of stored samples.
Biobank personnel and equipment
Since being able to assure high quality biospecimen is important for the biobank,
it is necessary to train all personnel involved in handling the sample during the
collection, processing, annotation, storage and distribution step [25]. Apart from
regular training also certification for staff and the relationship between different
personnel types need to be defined [25, 36]. Each staff member should be trained
according to the skills needed for their job and should receive training whenever new
technology becomes available or new practices are introduced [31]. Figure 3.6 shows
the influence on sample quality that the personnel and equipment have during any
process of sample handling.
Furthermore, also the internal laboratory and its specially trained staff need to be
certified to guarantee high-quality samples in the biobank. One approach is SPIDIA
(Standardization and improvement of generic Pre-analytical tools and procedures for
In-vitro DIAgnostics), an initiative launched in Europe to develop standardization
and improvement of pre-analytical procedures for in-vitro diagnostics [66]. In the
SPIDIA pilot study, molecular diagnostics laboratories are isolating nucleic acids
from standard blood and plasma samples [36, 62]. The isolated nucleic acids are
then analyzed in centralized facilities and their quality assessed. Laboratories with
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Figure 3.6: Influence of qualified or not qualified personnel and properly maintained equip-
ment or equipment with outdated support on the sample quality.
poor pre-analytical performance are guided on how to improve the reliability of their
procedures and are invited to participate in SPIDIA training courses [62]. To directly
support enhanced patient care for personalized medicine, the internal biobank labo-
ratory can get for example Clinical Laboratory Improvement Amendments (CLIA)
Certification and College of American Pathologists (CAP) Accreditation [67]. This
does not only enable the use of the banked samples for clinical patient management
but also increases the confidence of patients and physicians in the biobank [68].
Technology can help to ensure biospecimen quality, and there are many examples
in biobanks such as reliable freezers with monitoring and alarm systems, automation,
or various laboratory devices [36]. However, all this equipment needs up-to-date in-
structions for use and maintenance as well as appropriate personnel to use it [31].
All equipment needs to be maintained and calibrated regularly and service records
are to be kept by the quality manager.
Every person who handles a sample needs to be trained and all equipment need
to work as intended to minimize unpredictable and undocumented influence on the
sample that could lower its quality. Biobank staff need to be aware of the importance
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that sample quality has on future research and the resulting influence on person-
alized medicine. Therefore, staff members have to avoid mistakes and document
the procedures along the way of the biobanked sample. The likelihood of mistakes
can be reduced through periodic training and staff members can earn certificates on
proper treatment of samples. Having certified people working in the biobank will
increase the trust in the biobank and through this its value.
However, for cases where biobank staff can be substituted through automation
processes, this can be used to increase the processing quality. Automation will
decrease the treatment variability that is natural with human work and lead to
more comparable samples. However, the downside of automation is that it requires
regular maintenance and calibration. If the device is not set up properly, an error
could spread fast through the samples before it is detected.
Pre-analytical variation
Research results often depend on situations arising prior to sample usage [31]. These
are called pre-analytical variations. There are two parts to the pre-analytical phase:
the pre-acquisition phase and the acquisition phase [41]. The pre-acquisition phase
is the time, when the sample is not yet under supervision and control of biobank
personnel, while during the acquisition phase it already is. Circumstances that need
to be considered during the pre-acquisition phase include for example the treatment
the donor was given prior to the collection of the sample, such as drug treatments
with antibiotics, anticoagulants, or anesthetics. In the acquisition phase the lag
time – the time between removal of the specimen from the body until it is frozen –
and other sample processing steps are important [20]. While it is known that even
small pre-analytical variation can significantly influence the downstream results, it is
difficult to minimize these variations [20,43]. To ensure interoperability regardless of
these variations, it is needed to monitor and document the pre-analytical phase [43].
To facilitate the recording of such information the Sample PREanalytical Code
(SPREC) has been developed [36].
The SPREC can be applied to primary samples and their simple derivatives from
either solid tissues or fluids. Primary samples are samples that are directly collected
from the donor and simple derivatives are samples that are prepared through a
simple laboratory manipulation such as centrifugation of fluids or cutting of solid
tissue samples. Complex derivatives are samples for which preparation multiple steps
or chemical substances, such as nucleic acids, proteins, cultured cells, and others
are used. Complex derivatives, however, are not covered by SPREC. Furthermore,
there are no elements about freeze-thaw cycles or storage procedures included in
the SPREC because the code is already applied during the processing and labeling
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procedure. The code consists of seven elements which correspond to pre-analytical
variables as seen in Table 3.3. [69]
Table 3.3: SPREC for fluids (fluid biospecimen – supernatants and/or fluid-derived cells)
and solid tissues (or tissue-derived cytologic biospecimen) [69].
fluids solid tissue
First code element type of sample type of sample
Second code element type of primary container type of collection
Third code element precentrifugation warm ischemia time
Fourth code element centrifugation cold ischemia time
Fifth code element second centrifugation fixation type
Sixth code element postcentrifugation fixation time
Seventh code element storage condition storage condition
The SPREC gives important information about the pre-analytical variations that
should be mentioned in the documentation of biospecimen. Whoever uses this sam-
ple will know exactly under what conditions the sample was collected. Nevertheless,
there are some shortcomings of the SPREC. So far, the SPREC is not usable for
complex derivatives of samples, even though it would be especially useful for pro-
cessing nucleic acids to have proper documentation to estimate sample quality. The
other problem with the SPREC is that it only takes the acquisition phase into ac-
count. Drug treatment that patient received prior to sample collection or any other
habit that could influence sample quality are not recorded with SPREC.
Quality control parameter
One way to deal with unknown sample quality is the definition of quality control
parameters that can be used to compare and ensure certain quality. Since the quality
of samples can only be specified in the context of their intended use, there are
different quality control parameters for morphological, genomic, transcriptomic, or
metabolomic analyses [38]. Relevant parameters for nucleic acids for example would
be the total yield and the largest fragment length that can be extracted while the
protein quality depends on sustained antigenicity, preservation of biological activity,
and post-translational modifications. For this, the analysis of a variety of molecular
components is important [36]. It can be performed by using biomarkers for sample
quality.
A biomarker giving an on/off response can be used as quality indicator to deter-
mine the suitability of a sample for a certain research technique [41]. Ideal quality
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control biomarkers should furthermore be ubiquitous and measurable with generally
accessible methods [70]. Analyzing the response of such biomarkers can be used to
see differences in pre-analytical sample handling and processing [43]. Additionally,
they can also be used to reveal if samples were stored and handled as described
during their lifetime [41]. For accurate results, biomarkers need to be found for any
sample type and any derivative, and end product.
However, before being able to use biomarkers as quality control tools, it is nec-
essary to identify the quality markers which reflect factors that affect the sample
composition with sufficient accuracy and efficiency. After the identification of mark-
ers, quality consensus conferences involving stakeholders of national and interna-
tional biobank collaborations have to decide which of them can be used for quality
control. [43]
The usage of biomarkers as quality control tools for pre-analytical and storage
conditions will improve the interoperability of biobanks [43]. Having known qual-
ity samples and testing methods for quality control enhances the comparability of
studies and research results [70].
Knowing some factors that can be tested to ensure the quality of a sample for
certain research techniques, will be a big help for researchers. If the quality relevant
elements from the pre-analytical phase are properly documented, researchers can
directly ask for samples with certain quality properties. This will save time and avoid
unnecessary usage of samples and lead to high-quality research results. Elements
related to storage and shipping conditions are usually not tested before the sample
reaches the researcher. So a quick test for quality relevant factors to check the
usability of the sample needs to be in place.
Quality control biomarkers can be used to identify the influence of some factors
to sample quality. They provide a good method to check for quality features in the
sample. They can further be used for sample monitoring over time and in research
to find the ideal storage condition for different sample types. I think quality control
biomarkers will become especially useful if they are affordable and can be detected
and evaluated with simple methods or tests in every laboratory.
Documentation and tracking
Since sample quality is relative to the research question asked, a biobank might have
multiple samples of different quality level [3]. This makes proper documentation es-
sential because it permits the assessment of sample properties later on. The value
of the samples in a biobank is therefore not only defined by their physical qualities
but also by the abundance and quality of the associated data [20]. Recording and
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tracking each known step in the biosample’s lifetime is very important since incom-
plete or incorrect documented data could lead to low value samples and possibly
influence study results. To avoid decreasing sample quality through incomplete doc-
umentation some crucial information needs to be recorded including treatments and
outcome of each treatment, diagnosis, time of sampling, type of primary collection
tube, delays, and temperatures of processing and storing the samples [20,41].
Other important information that should be documented include any unexpected
events along the biobanking process such as unforeseen temperature shifts during
storage or transport [41]. Repeatedly during the lifetime of a sample, quality re-
views should be performed to verify the integrity of the sample [34]. Furthermore,
bar-code tracking should be used to ensure traceability of the sample collection and
processing and reduce the error potential of tracking samples by hand [41].
By recording every step during a sample’s lifetime, the processes possibly influencing
the sample quality are also recorded. This can result in a huge amount of data. This
data, however, should be manageable and accessible with proper recording in the
database of the biobank. Especially when considering future research with new
techniques, this information could potentially become important when new factors
are identified that can influence sample quality and research results.
Researchers who are interested in ordering a sample, need to be able to search for
the recorded factors that could influence sample quality. Furthermore, researchers
should be able to track samples to find other samples from the same collection
with the same or different properties. Good documentation simplifies database
management, which in turn is important to have an accessible database that properly
presents the sample collection. Well presented samples along with searchable variety
of sample properties will increase the usage of the biobank.
3.2.3 Coordinated governance and regulations
The term regulation is often used interchangeable with governance in the context of
biobanking. However, the scope of regulation is more narrow and applies only to the
formal structures of law and legally constituted regulatory bodies [37, 45]. In case
of biobanking, governance is understood to be an interaction network along the sci-
entific/technological, the medical/health, the industrial/economic, the legal/ethical,
and the social/political field [3,25]. This means biobanking governance is concerned
with all processes governing the biobanking structure. This includes the develop-
ment of standardized protocols for different routine activities in the biobank such
as data and sample handling, training of the personnel working at the biobank, and
the development of a bioinformatics system for operating the biobank as well as for
data management and data access for different stakeholders [25].
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Another part handled in biobanking governance is to have biobanks tightly con-
nected with the health care system in order to support personalized medicine. There-
fore, clinicians and hospital administrations should be involved in the governance
and financing of biobanks because they will benefit from the advantages personalized
medicine will be able to offer. [68]
Biobanking projects tend to be expensive considering the high investments for
setting up the biobank and high maintenance costs for facility, storage, and person-
nel [25]. Therefore, biobanking governance has to create solid business models for
biobanks to ensure funding, operation, and utilization of the biobank. This issue is
further discussed in Chapter 3.2.5.
Due to the undeniable link between biobanks and bodies, ethical issues are also
part of biobanking governance which include consent, privacy, autonomy, and confi-
dentiality features. Biobanking governance has to include RECs or IRBs which are
responsible for approving the establishment of the biobank, as well as approving any
research using samples and/or information from the biobank. [37, 71]
Furthermore, biobanking governance is supposed to communicate biobanking re-
search openly and transparently and to establish a trusting relationship with the
public. Through higher trust in governance, people will develop a more positive
attitude towards biobanking and are more likely to support it. [19]
Biobanks should develop a governance plan which describes their oversight and
structure, including the roles and responsibilities of parties involved in the biobank-
ing processes [51]. The governance plan is needed for researchers, clinicians, and the
public to know what the purpose of a sample collection is. Important elements that
should be described in the governance plan are shown in Figure 3.7.
Especially in the times of cooperation between biobanks and data sharing, a
good governance plan is important [37]. Without a plan and policies to follow
human rights and data protection laws, a biobank cannot legally share data or
samples in a network. However, the current structures of biobanking governance
are not developed for networks and do not allow for the flow of samples and data
at a global level [45]. Most governance systems are still based on national laws,
creating boundaries on international use and interoperability with other biobanks.
This creates problems since there is no unified governance system for samples and
no harmonization for most of the national laws and regulations, except for the law
of data protection [19]. To overcome the legal differences resulting from dissimilar
national laws between European countries, the EU suggested to create a common
legal framework for biobanking in 2009 [37]. As for March 2014, the BBMRI states
that it will be implemented under the European Research Infrastructure Consortium
(ERIC) [72]. BBMRI-ERIC foresees a headquarter in Austria which coordinates the
interaction of the so called national hubs in several of the member states. Each of
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Figure 3.7: Elements of a governance plan. The governance plan needs to provide informa-
tion on the leading board of the biobank as well as the advisory board and the REC and/or
IRB that is in charge. The boards are made up of specialists in the scientific/technological,
medical/health, industrial/economic, legal/ethical, and the social/political field. They are
needed to ensure all aspects of this interdisciplinary structure. Furthermore, the gov-
ernance plan has to present the database management, economic management, quality
management, sample management, and access regulations. It also needs to list the stan-
dards used in the biobanking processes of collection, processing, storage, and distribution
of samples, as well as the ethical regulations for consent and privacy protections.
these national hubs is also established under ERIC and its task is to link its national
scientific community to BBMRI-ERIC. Through this collaboration under a common
legal framework, BBMRI-ERIC is expected to increase the efficacy and excellence
of biomedical research in Europe.
However, also on the level of individual biobanks there are suggestions of what has
to be changed to get biobanking governance to the modern standard to efficiently
support personalized medicine. The embedding of biobanks in clinical care is one of
these changes needed. It is important for personalized medicine and will also ensure
financial sustainability and attractiveness of biobanks for clinicians, researchers, and
the industry. Furthermore, using e-governance solutions could improve many pro-
cesses. One example is to use e-governance in case of interaction with participants
for dynamic consent. Another one is the use of digital identifiers for biobanks that
can then be used in publications and funding grants to reference the custodians. [37]
The governance structure is important because through it, the biobank presents
itself. This is why I think it is important to have a good coordinated and transparent
governance structure at hand with appropriate oversight bodies.
There needs to be a clear structure of the people in charge of the components of
the biobank. This will increase the trust that the public has in a biobank because
they can see who is behind the sample and data collection. Furthermore, they can
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familiarize themselves with the regulations the biobank has in place that ensure
their data and privacy protection. It would be good if funding institutions required
a governance plan from the biobank before deciding to support them. Through this
they can estimate the probability for success of the biobank and therefore determine
the risk they run with an investment.
Another issue is that a lot of documents and forms for applications for research
studies and others are still paper based. Even the oversight bodies are still working
with paper documents that might have to be digitalized later to make it more
easily accessible. However, time and resources could be saved by using for example
electronic forms to fill research applications. A computer program could already
pre-screen the application to make sure everything necessary is filled out and sort
it according to its purpose. This will make it easier for researchers that will know
right away if their application is complete and will be processed or if they missed
something. Also the responsible people in the relevant oversight body will only get
complete applications that concern their area of expertise.
3.2.4 Dynamic creation and destruction
Biobanking is not a finished invention but is a highly complex, interactive, and
dynamic multi-disciplinary field of science [37]. Through progress in genomic re-
search, technological advances, development of new laws more accurately adapted
to biobanking research, as well as improved standards, guidelines and best practices,
there is constant movement and evolution in biobanking governance [25]. Further-
more, the public’s opinion on methods of research can change over time and differ
between countries [3]. Each new proposal, development, or invention in one of the
areas of biobanking will potentially affect the others, leaving the need for constant
adjustment. Therefore, biobanks have to be designed, constructed, managed, and
funded with flexibility, sustainability, and international interoperability [24].
Several aspects have to be taken into consideration to keep biobanks and biobank-
ing research active and dynamic [24]. Interoperability of biobanks as already men-
tioned is important for a more robust, more efficient, and more flexible research
structure, which helps to pool, share, and analyze information and biological sam-
ples between them [20]. To be able to cooperate with other biobanks there is a need
for flexible guidelines which can be harmonized [37].
Due to the nature of biobanks and biobanking research, a dynamic and flexible struc-
ture is needed. A biobank is in my opinion doomed if it cannot adapt to changes
since there will constantly be new developments as biobanking is – as described in
this thesis – a relatively new venture.
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However, allowing for change is not as easy as it might sound. A biobank is
governed by its governance plan where the regulations and laws to be followed are
listed. This plan is approved by oversight bodies that make sure that for example
data and privacy protections are in place and that donors’ rights are protected.
Therefore, it is very important to try to consider future changes and leave the
possibility to modify given structures in the governance plan and in the biobank’s
legal documents.
3.2.5 Economic analysis
Funding difficulties, changing market needs, and the need to create a fitting business
model on which to achieve long-term sustainability, make financing one of the most
challenging aspects regarding biobanks [20]. The main problem is the high costs
for setting up a biobank and maintaining it [25]. One way to afford these costs is
to get adequate funding for the biobank [36]. There is a need for long-term secure
funding for establishing and maintaining biobanks and biobanking research [34]. To
achieve this, there are several funding models that are used by biobanks such as the
entrepreneurial model, the biosocial model, or the public model [3]. An overview
over these three models is given in Figure 3.8 and they are explained in detail in the
following.
Biobank Biobank Biobank
Public state 
institutions
Commercial 
institutions
Patient activist group for disease A Government
other funding institutions
A not A
Entrepreneurial model Biosocial model Public model
Figure 3.8: Comparison of the three funding models: entrepreneurial model, biosocial
model, and public model. Displayed are the funding types for each model and which
funding types get public support (+) and which get public opposition (−).
The entrepreneurial model is a collaboration between a commercially oriented
organization and public state institutions [3]. Through the cooperation with public
institutions it is hoped to catch the support of the people since public support is
also needed for the sustainability of biobanks [25]. Biobanks that have commercially
oriented funding often have the problem of little public support due to the com-
mercialization of the stored tissues [73]. Participants may not support commercial
research because it can lead to the undermining of the equality of biobank benefits
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through the development of expensive therapies and diagnostic tests. Therefore, the
entrepreneurial model has turned out to be more challenging than expected [3].
The biosocial model is promoted and funded by patient activist groups who are
often creating and operating biobanks as well. It has proven to be a stable model
for funding of biobanking research. However, since it is run by a specific patient
activist group, research in their disease areas is favored. This can lead to a limi-
tation of general biobanking research and an uneven distribution of samples. On
the other hand, this model is important for the biological faith of citizens that are
neglected in public health schemes because it can specifically represent that part of
the population. The main problem of the biosocial model is that the funding patient
activist groups themselves are dependent on financial donations. This leads to high
uncertainty in this kind of financial support for biobanks. [3]
The most commonly used funding model for biobanks is the public model [1, 3]:
biobanks are supported through taxpayers’ money and non-profit funding organi-
zations. It is often argued that due to the impact that personalized medicine will
have on the health care sector, the government should fund biobanks and biobank-
ing research [3]. Getting the government as main funder helps to shield projects
from corporate influence [74]. However, one issue with this funding model is that
its support depends on politics and can be lost if voters have no more confidence in
the promise of personalized medicine and other important outcomes from biobank-
ing research [3]. Overall, publicly funded projects are regarded trustworthy by
the population, which is important for the support, especially for population-based
biobanks [37]. The public model for funding also gives importance to data and
sample sharing [43]. Publicly funded biobanks are widely seen as data and sample
collections for the promotion of scientific research for the public good [24]. The
resources funded by the public should be made accessible to as many researchers as
possible to eventually maximize the benefits for society [45].
However, with the unsteady economic climate, it is often difficult to find potential
investors for a project like a biobank [20]. This reluctance is mainly coming from the
fact that there are not only start-up costs for the biobank facilities but running a
biobank also requires a huge amount of investment with usually little returns [73,75].
To still find funding organizations there have to be proposals of cost recovery in the
biobank’s business model [25]. It is important for biobanks to create some kind of
value that can be used for cost recovery [25]. One way is commercially by selling
data by itself, licensing biospecimen or research services for research institutions, or
offering collaboration to other biobanks [20, 34, 73]. Another often underestimated
value is that of the samples that are stored in the biobank [34]. Rare samples or
samples of very high quality have high value because they are more demanded than
average quality samples that are available in large quantities. Therefore, having
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the right samples according to the market need will attract more customers to the
biobank, increasing its reputation and making it appealing to funding organizations
to invest money.
In 2011, Vaught et al. presented an example for a sustainable business model for
human tissue banks. They suggested that the main parts that need to be considered
in the economic model for a biobank are 1) understanding the market need for the
biobank type, and 2) effectively managing the value chain of the biobank. The five
key factors in a biobank’s value chain are the collection of samples, the processing
of samples, their storage, their distribution, and the infrastructure and administra-
tion. With the help of these factors the Total Life Cycle Cost of Ownership (TLCO)
model can be calculated. The purpose of the TLCO is to estimate all costs coming
from owning, operating, and maintaining the biobank through-out its life time. A
business model with this information is important for prospective funding institu-
tions to see how the money will be spent and makes the financial aspect behind the
biobank more transparent. [34]
It is important for biobanking projects that rely on funding to inform funders about
their financial situation. At the start of the project there has to be a sustainable
economic plan which includes the overall costs and the planned cost management.
During the lifetime of the project regular financial reports have to be published to
display transparency of the project. Therefore, the biobank needs to have a business
model, where among other things, a cost estimation, the planned cost management,
the frequency and content of financial reports, and a tool to easily report on finances
periodically is determined. I think the value chain elements as suggested by Vaught
et al. make up the main cost factors in the biobank and therefore are important
elements for the TLCO. The TLCO is a reasonable way to show the cost estimates
for operating and investment costs. Providing a TLCO in the business model will
make a biobank’s finances comparable and clearly state cost over time for possible
funders.
Furthermore, the business model should state what kind of cost recovery mecha-
nisms the biobank is using. While it is a good idea to not fully depend on funding
organizations I think one problem is that especially the licensing of biosamples can
be regarded as exploiting volunteers. One tries to make profit from something that
was voluntarily donated to help solving research questions and improve treatments
and drugs for the good of the public. Especially for publicly funded biobanks there
should not be any profit made directly from samples or data that is stored. There
are still other ways for cost recovery, for example by offering pre-processed samples
such as extracted DNA or RNA from the sample, organizing trainings for research
laboratory staff, or renting freezer space to other institutions.
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3.3 Research component
The third and last component of the triangle model is the research component. As
shown in Figure 3.9, it consists of two parts; the training and certification of research
laboratories and the reporting of research results.
While biobank institutions can do their own research, most other sample col-
lections have researchers and laboratories not directly linked to the collection that
use the samples in their studies. To make the best out of all sample collections, re-
searchers and laboratories should use them under high quality standards and provide
feedback about their results.
Personalized medicine
Biobanking
  
Research
Public component
Research component
Biobank component
● Training and certification
● Reporting
Figure 3.9: Triangle model: detailed view of the research component with its parts.
3.3.1 Training and certification
While training for biobanking staff and certification of biobank intern laboratories
is important to assure high quality samples (as mentioned in Chapter 3.2.2), there
are no training or certification requirements mentioned for researchers and their lab-
oratories that want to conduct further research with biospecimen from a biobank.
However, knowing about training and certification of a researcher or a laboratory
that applies for the use of samples, can be helpful when deciding on the granting
of access to the biobank. The only restriction for research laboratories that is men-
tioned in the literature, is that if they are not CLIA-certified, they cannot report
patient test results or use banked samples for patient management [68]. The SPIDIA
training can also be applied to researchers and laboratories that are using samples
from a biobank to maintain the sample quality [66].
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To have high quality results, the provided samples must be of high quality but also
the laboratory that handles them must do high quality research. The quality of re-
search can be estimated with training and certification documents provided by the
research institution. In my opinion, there are two areas where certifications of a lab-
oratory can be used to make decisions; when applying for the use of rare samples and
when other researchers want to rely on stored previous research results. Biobanks
should be conscious of the reputation that they will get through the publication
of good research results from laboratories that have used the biobanks’ provided
samples. Therefore, biobanks want to make sure that researchers and laboratories
that receive their samples have high standards and are certified and well trained to
ensure high quality research and respective results.
When it comes to applying for the sample usage for research, researchers can
give with the proposed research plan also the certification of their laboratory and
their personal certification and trainings to show the biobank their capability of high
quality research. Especially for rare and non-renewable samples there has to be a way
for biobanks to prioritize who will get the sample wherefore such information on the
laboratory and the researchers are important for decision making. How a biobank
decides about the access regulations is as mentioned part of the governance plan.
Furthermore, when publishing or sharing results, the information on certification
and training of the researchers is an important criteria to evaluate trustworthiness
and quality of the results.
3.3.2 Reporting
There are three different forms of reporting. The first one is sharing the information
and individual results with the participant. The second one is sharing the research
results with other researchers and the third one is publishing the study results in
scientific publications. In Figure 3.10 the three result types and the way of reporting
them are summarized while they are discussed in more depth in the following.
Results for individuals
The Declaration of Helsinki states that participants who donate samples have the
right to know about the general outcome of the study their samples were used
in [29]. However, there is no specific saying that they also have the right to receive
information about individual results.
Biobanks often return individual results of diagnostic tests and biometrics con-
ducted for the participation in a biobanking study. However, there is still a lot of
controversy regarding the return of genetic or genomic results to participants. It is
agreed that if individual results are going to be returned they need to be scientifically
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Figure 3.10: Summary of the different results that are encountered while conducting re-
search and how the reporting on these results is discussed and proposed to be handled in
the literature. First, one might make findings about single samples that could be shared
with the donor. Then, after all the samples for a study have been investigated, the results
of the study could be presented and further on these results could be published.
validated and the nature of the results need to be examined with regards to the risk
for the individual to develop a condition, the severity of that condition, and avail-
able treatment options. The recommendation is to consider the risks and benefits
as well as ensuring the validity of the data before the results are returned. [28]
Research shows that participants in general want to know their personal research
results. A special problem occurs with genetic and genomic results because of the
impact they might have on genetic relatives or on the health of a future child. This
brings up the question for researchers if they are ethically responsible to return such
results. This is especially difficult in cases where people do not want to know about
their results: their right to not know has to be respected even though knowing and
finding early treatment could improve their life expectancy for example. [35]
Other issues arise with the sharing of samples. It is unclear who is responsible
for informing the participant about research results: is it the researcher who got the
results or the one who originally collected the sample [28]? Another concern is the
understanding of the meaning of the results [35]. A genetic counselor is needed to
properly prepare a participant and inform them about results and their probable
impact [76].
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Since the donation of biosamples for research is done voluntarily, it is understandable
that participants want to know about the results of the study or research their
samples were used for. When talking about sharing individual results, however, it
gets more complicated. It is highly possible that participants want to know if they
have a risk for a certain disease and there should be some way to communicate
such findings. However, informing participants about individual findings requires
additional effort from the laboratories. If the research laboratories want to offer
personal research results there should be a way for the participants to mark in the
consent form if they want to be recontacted in case of any findings. This wish as it
is marked should be respected in both ways, in case they want and in case they do
not want any information.
Results for researcher
One problem of sharing genetics research results is the amount of work that is as-
sociated with it. Another one is the wish of every researcher to protect the current
research and possible findings and publications from other laboratories. [52]
However, to avoid that researchers working with one sample have to redo certain
tests over and over again, it would be useful to share results with each other. The
database in a biobank is the ideal tool for result sharing. Any information related
to the sample, sample handling, sample processing as well as results for certain tests
and who conducted them can be stored. I believe that there are several advantages
for research if previous research results are available.
Accessing these information allows researchers to use previously conducted tests
and their results to shorten their own research duration. Alternatively, they can
compare results they got in their laboratory with the ones that had been previously
stored. This can be used to verify study results and it allows also to see how
samples change over time and how this affects research results. Another advantage
is that by storing also the information of the researcher and the laboratory that had
performed the tests and recorded the results, researchers can easily get in touch with
each other. This can help to understand the reasoning behind conducting research
in a certain fashion, get additional information on the research, and even lead to
new cooperations between researchers and laboratories.
Scientific publications
The information about research results of biobanking studies is generally made avail-
able in the form of publications in scientific journals [76]. One of the problems these
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publications are facing is the recognition of the involved biobank [37]. While many
journals require the acknowledgment of the data provider, it is left up to researchers
who usually follow the norms of their field. A possible solution is to provide a unique
identifier to each biobank which can be used to cite and acknowledge the use of these
biobanks in publications and funding grants [37,71].
Another problem is that it is not clear how much information on the used samples
have to be provided when publishing research results. Biobanking experts say that
researchers give little thought to sample quality and many do not include information
about the obtaining, storing, or processing procedures in publications [33]. Having
different or no information on these parts makes it difficult to compare studies [36].
There has to be a standardized way of data reporting and including in publications
which journals should enforce [24, 33]. To address this problem the Biospecimen
Reporting for Improved Study Quality (BRISQ) recommendations are introduced
which apply to any study including biospecimen [77]. The BRISQ list consists of
recommended data elements to report in journal publications which include gen-
eral biospecimen information and factors that could influence the integrity, quality,
and/or molecular composition of the biospecimen. The list is intended to help to
report information on the handling of biospecimen in an accurate and standardized
way. In addition, any formal certification or accreditation the laboratory was oper-
ating under should be reported. This list as first published in 2011 is the first step
in defining general reporting recommendations and will evolve over time.
Scientific articles are a way to become known in the community and to present
yourself and your study results to the world. When reporting on research, however,
not only the results are important but also the materials used.
When biobanks are involved, it is important to give them recognition by mention-
ing the biobank used and details about the sample. Since most of the information is
stored in the database, one solution I suggest is the automatic creation of informa-
tion files on the samples used. There need to be standards about what information
should be reported and the database could then directly provide a collection of
them. Ideally the researcher can download them in a table already formatted for a
given form of publication that can then be just added as appendix for example. The
BRISQ list can be a good starting point in deciding which information should be
available in publications. By having a standard list of information about samples
used in research for publications, it would help to make research more transparent
and allow for studies and results to be comparable, repeatable, and verifiable.
41
4. DISCUSSION
The individual parts of the three components of the triangle model were discussed
in the previous sections in comparison with my thought experiment that laid their
foundation. In this section I focus on those parts that have not been mentioned in
the revised literature or are not even developed.
Furthermore, I take a look at the situation in Finland. Finland has only recently
implemented a new law on biobanks. Therefore, I want to discuss, how parts of the
triangle model are used in the Finnish biobanking and health care system.
4.1 What is missing?
Much has been done in the area of biobanking to support personalized medicine.
However, when working on the development of the triangle model, I came across
some issues that are to the best of my knowledge still missing.
There are basically four parts that require attention. They are concerned with:
the governance plan and its components, details in quality control management, the
usage of information technology in biobanking, and the reporting mechanisms in
scientific publications.
4.1.1 Governance plan
The governance plan for a biobank is essential for its transparency to the public,
researchers, other biobanks in a biobanking network, and funding institutions. The
governance plan is needed for funding institutions to know what they are funding,
and for the public to know, who is in charge and what the participants’ rights are
when taking part in a biobanking study and donating samples. The governance plan
should include in addition to information about the biobank’s administration the
following information:
• ethical regulations for consent type and privacy protection,
• sample management and access requirements to samples and data,
• standards and best practice guidelines that are used in the biobanking process,
• quality and database management, and
• economic management including a business model for the economic analysis.
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However, the parts of the governance plans that are currently available focus only
on the first two points about ethical and legal aspects of biobanking. It is true
that they make up an important part to governance since they are the parts closest
linked to laws and regulations. Yet, the other parts are just as important but are
not featured in currently available governance plans.
Knowing the standards and best practice guidelines applied in a biobank and
the included quality and database management plans help other biobanks and re-
searchers to estimate the sample quality that they can expect from that biobank
and the data security and safety. It ensures them that proper measures are taken
to guarantee the quality of samples and corresponding data.
There have been suggestions for business models for the economic analysis of
biobanks [3], however it is important to include financial models to the governance
plan. This helps funding institutions in particular to understand where the money is
used. In addition to that, a standardized financial analysis plan such as the TLCO
model is required. It could render spendings of different biobanks comparable.
One important aspect of biobanks is the dynamic creation and destruction as
stated in Chapter 3.2.4. Since the governance plan is the internal law the biobank
has to follow, it is important that it allows for the flexibility that the biobank needs.
The more precise the governance plan states its regulations, the more difficult it is
for the biobank to maintain a certain flexibility and adapt to changes if there is no
exception statement included. An exception statement allows to change regulations
through the inclusion of RECs or IRBs in the governance plan which will ensure the
observance of ethical and legal values.
4.1.2 Quality control
While the quality management plan is supposed to be listed as one of the best
practice guidelines, there are more parts missing in current quality control. More
quality control parameters, especially biomarkers for different sample types and for
the use with different techniques need to be found. Furthermore, the proposed
SPREC is so far not valid for the case of complex derivatives. This, however would
be of importance: for example, nucleic acids are complex derivatives and play a
significant role in genetics and genomic research as parts of personalized medicine.
The SPREC code should be stored with each sample aliquot. However, the storage
conditions and freeze-thaw cycles should be documented as well because they can
influence sample quality, too.
Sample tracking is important for quality control but is mostly done by the biobank
personnel. With the help of a barcode they can scan an item to recognize it, store
the scanning time and place to track the sample during shipping, and whenever
adding information to the sample’s data in the database. The scanning of the
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barcode prevents mix up errors of sample information through typos when having
to copy the unique identifier for example. However, tracking also needs to be able for
researchers directly through the interface they are using when accessing the biobank.
For research it is sometimes important to repeat tests with an aliquot from the same
sample that was stored under either the same or different conditions. Therefore, a
way has to be provided to track the sample and find aliquots of either the same or
a different processing batch.
Every information on sample handling, the SPREC, and tracking information
have to be stored with the corresponding sample. Many steps need to be documented
during the lifetime of a sample; however, so far the decision whether or not to
document depends mostly on the people who handle the samples and the opinion,
how important they think a certain step or condition is. Obviously, there are clear
standards missing describing what information needs to be documented and stored
with each sample. This is of importance to researchers so that they can query the
database to find samples that have gone through certain steps in their processing,
have specific characteristics, or are of well defined quality.
4.1.3 Using information technology
Storing data in large databases has become easier through recent advances in in-
formation technology. Biobank database systems allow not only for storing large
amounts of text data, but also for adding electronic forms, reports, images, and
other data types to a database entry.
This possibility calls for e-governance systems, which allow for electronic forms to
be filled and submitted online on the web interface of the biobank. If available, there
should be a direct link from the database to the electronic medical health record.
To make this more secure and to prohibit access to personal or other restricted
information, only certain fields from the record could be accessible. For the case
that a researcher wants to access other fields, there could be an application form
provided where the reason for such access could be stated, which is then verified by
an ethics committee. Electronic consent forms could include educational movies to
explain the procedure, and could even be signed through an electronic signature.
Another idea is the provision of dynamic consent, where participants can access
their sample’s information through a web interface and give continuous consent for
research. However, this requires further security considerations. While the web
access for dynamic consent would be used from a private computer, the original
consent form will still be filled at the institution where the sample is collected which
will allow for higher data security.
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4.1.4 Reporting in scientific publications
Scientific publications on research with biobanked samples require clear reporting
guidelines that have to be enforced by journals. So far, this was mostly left up to
the researcher and treated according to standards from their respective field.
A standard for the minimal set of information about a biosample is needed and
has to be accepted by journals. As soon as this minimal set and possible extensions
are defined, a standard based on the eXtensible Markup Language (XML) could
be used. The biobank could then allow to retrieve the required information in this
form. It could be attached to a publication in the appendix or as an additional
information file.
Another issue is that it is general consent that publications should contain a
reference to the biobank and the biosamples which were used. However, the used
samples should also provide a link to the published article, so that researchers using
a sample can see which types of studies have been done with the sample and where
to read about them.
4.2 View on Finland
After this general approach, it is interesting to see how the triangle model can be used
in the example of Finnish biobanks. The Finnish biobanking system has recently
been changed through the Biobank Act (Act 688/2012) [78], which was approved
on October 2, 2012 by the Finnish Parliament and came into force on September 1,
2013 [79]. According to Sirpa Soini, a legal adviser for the Finnish national biobank
coordination and a member of the Governmental Expert Steering Group for the
Implementation of the Biobanking Act, this is the first such law in Europe which is
applied to all biobanks independent of their type and purpose [80]. Other biobank
regulations are usually type specific, leading to different regulations in case of for
example tissue banks, blood banks, population-based, or disease-oriented biobanks.
Finnish biobanks are also going to be part of the BBMRI network with BBMRI.fi
as their national node. On March 10, 2014, Auria Biobank and THL Biobank
have been registered in the national biobank registry of the National Supervisory
Authority for Welfare and Health (VALVIRA), making them the first two official
biobanks in Finland in accordance with the Biobank Act. [79]
Comparing the information available on the requirements for Finnish biobanks
and their set up with the triangle model brings the following results:
• Information on biobanks in general and specifically on donor rights, consent,
and data protection is available for the public. The topics, the public is most
concerned about are explained in a short and easy understandable manner on
the web page about biobanks in Finland in Finnish, English and Swedish. [81]
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• The Biobank Act makes it possible to ask for consent for unspecified future re-
search. This so called biobank-specific consent allows the inclusion of samples
and data to several projects in one specified biobank infrastructure. However,
participants have to be informed on the voluntary nature of participation,
biobanking in general, potential risks, the reason for the collection and stor-
age, as well as on their rights to cancel or limit their consent at any time.
Furthermore, due to the strong link of samples and data to the biobank, par-
ticipants need to be informed about the owner of the biobank and the biobank
itself. [80]
• There is no information available on the specific governance of the Auria
Biobank while information on the THL Biobank is only available in Finnish.
However, BBMRI.fi states that biobanking activity is governed by five laws:
the Biobank Law, the Law on the Medical use of Human Organs, Tissues and
Cells, the Law on the Status and Rights of the Patient, the Medical Research
Law, and the Personal Data Act. Furthermore, it states the National Supervi-
sory Authority for Welfare and Health (VALVIRA), the National Committee
on Medical Research Ethics (TUKIJA), and the applicable regional ethical
committees as authorities to guide and monitor the biobanks. However, stan-
dards applied in the biobanking process, quality control mechanisms, or a
business model for the financial analysis of the biobanks are not explicitly
mentioned. [79,81]
• The Biobank Act describes biobanks as shared research resources. Therefore,
samples and data can be used for research if the intended use fits to the notified
field of research activities of a biobank and is consistent with the provided
consent. Only in a few cases, the restriction of delivery is justified, such as to
safeguard intellectual property rights, privacy or primary research, for reasons
related to research ethics, if the intended use is against a biobank’s field of
activity, and to preserve rare or limited collections for significant purposes.
These access criteria apply to both, internal and external research, and must
be transparent in the access policy. [80]
• According to the Biobank Act it is obligatory for the biobank to publish infor-
mation on their banked samples, their use in research projects and the results
of those projects. The goal is to have data accumulate in the biobank for other
researchers’ benefits. This would help to minimize analytical repetitions and
present a common platform for research findings. [80]
This shows that Finland’s biobanks already have a good structure to provide support
for personalized medicine, while the same issues remain missing as for all biobanks.
However, creating a network of same standard high quality biobanks is in my opinion
a good approach taken in Finland. It will make the BBMRI.fi a high quality node in
the BBMRI network and will allow high quality national interoperability of biobanks
as well as international collaborations through the BBMRI network.
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5. CONCLUSION
The motivation for this work was that to the best of my knowledge no scientific
publications exist that present all aspects that would be necessary for biobanking
and research to support the development of efficient personalized medicine. To fill
this gap in the literature I created and presented the triangle model in this thesis.
The biggest problem I experienced during the writing process was the relevance
of this topic. Continuously new articles are being published, biobanks are set up
or fail, and there are many people with various opinions on what is good or bad
practice. And even though there are many recent articles concerning biobanking and
biobank research there are some processes in biobanks that have their information
not published. Many times something that seemed to be missing was in fact already
used in practice in some other biobanks.
The triangle model was created based on a thought experiment after extensive
literature study. Every element of the model was presented, examined, and com-
pared to published information to find the elements or parts of the elements which
have not yet been developed or have not been regarded as important for biobanking
and research to support personalized medicine. From the previous chapters it can be
seen that there is indeed much information on most elements of the triangle model
and I found mainly four points that are missing. These are:
• the availability of a complete and flexible governance plan since only ethical
and legal aspects as well as access regulation are mentioned and corresponding
information accessible,
• proper standards for documentation and tracking of samples for quality con-
trol,
• use of electronic forms, and
• proper standards for reporting in scientific journals.
This model and the results from the analysis to find elements that are still missing
can be used as a base line for setting up a biobanking project in support of person-
alized medicine. The triangle model should stir up a discussion about the presented
components and lead to a development of the missing parts. Then, it can be used
as a guideline to support biobanking to lead to better personalized medicine.
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When asked whether biobanking is a model for success for the support for per-
sonalized medicine, I would say that I believe biobanking can become a model for
success but there is still work to be done. Especially for enhancing interoperability
between biobanks as well as research institutions and clinics there is a lot of work in
progress. The BBMRI is one big network in Europe that tries to provide a simplified
way of sharing data and samples among different national biospecimen collections.
However, the network is currently only in its establishing phase and only time will
tell if it will fulfill its promise.
Another issue I found during the literature review was that most authors see
a biobank as a standalone physical entity. This model of a biobank can poten-
tially cause problems if it is not in any way connected to a clinical or research
setting. There has to be a tight link between biobanking, research, and personalized
medicine, and standalone biobanks tend to miss what is needed for interoperability
in an interdisciplinary field. However, I do not believe those biobanks have to be a
failure. Through employing clinicians and researchers in their advisory board, for
example, a closer link to research and personalized medicine can be created. The
triangle model presents important aspects to connect these fields. Therefore, fol-
lowing the guidelines of the triangle model could help biobanks to become a more
successful support for personalized medicine.
The future of biobanks will depend on the usability of the stored information.
If no one uses the collections for research, or if the public does not support such
collections anymore, funding institutions will lose interest and biobanks might have
to close. However, at the moment this field is still in the collection phase where
new biobanks are established in almost every country. In a couple of years it will
be seen how many of them are used and if biobanking and research really support
personalized medicine.
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